A Phase II Study Assessing High-Dose Radiation Therapy plus Chemotherapy to Improve the Likelihood of Surgery for Locally Advanced Pancreatic Cancer

Full Title

Maximal Ablative Irradiation Because of Encasement (MAIBE) For Patients with Potentially Resectable Locally Advanced Pancreatic Cancer

Purpose

Radiation therapy plus chemotherapy is a standard treatment for locally advanced inoperable pancreatic cancer. In this study, researchers want to see if giving a radiation dose that is 50 percent higher than the standard dose, plus chemotherapy, can shrink tumors enough to make them surgically removable. In patients whose tumors remain inoperable, researchers want to see if the higher radiation dose helps them to live longer than the standard treatment.

All patients in this study will receive the higher radiation dose plus an oral drug called capecitabine. Patients whose tumors shrink sufficiently with this therapy will have surgery to remove the tumor; others will be observed to evaluate the effectiveness of the therapy on their survival.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have locally advanced pancreatic cancer that has invaded nearby blood vessels, making it inoperable.
  • Patients must have completed at least 3 months of induction chemotherapy within 6 weeks of entering the study.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Marsha Reyngold at 631-623-4267.

Protocol

18-090

Phase

II

Disease Status

Newly Diagnosed & Relapsed/Refractory

Investigator